The role of heat shock protein 60 (HSP60), a mitochondrial chaperone, in tumor progression or its anti-tumor effects remains controversial. This study aimed to confirm the possibility of using HSP60 as a prognostic marker in patients with colorectal cancer (CRC), considering TNM classification for precise prediction. HSP60 expression increased with differentiation and p53 mutations in patients. However, compared to patients with high HSP60 expression, patients with low HSP60 expression had event-free survival and disease-specific survival hazard ratios (HRs) of 1.42 and 1.69, respectively. Moreover, when the survival rate was analyzed by combining TNM classification and HSP60 expression, the prognosis was poor, particularly when HSP60 expression was low in the late/advanced stage. This pattern was also observed with HSP family D member 1,HSPD1, the gene that encodes HSP60. LowHSPD1expression was linked to lower overall survival and relapse-free survival rates, with HRs of 1.80 and 1.87, respectively. When TNM classification andHSPD1expression were considered, CRC patients with lowHSPD1expression and advanced malignancy had a poorer prognosis than those with highHSPD1expression. Thus,HSPD1/HSP60 can be a useful biomarker for a sophisticated survival prediction in late- and advanced-stage CRC, allowing the design of individualized treatment strategies.
热休克蛋白60（HSP60）作为一种线粒体伴侣蛋白，在肿瘤进展中的作用及其抗肿瘤效应仍存在争议。本研究旨在结合TNM分期以实现精准预测，探讨HSP60作为结直肠癌（CRC）患者预后标志物的可能性。结果显示，HSP60表达水平随患者肿瘤分化程度和p53突变状态升高而增加。然而，与HSP60高表达患者相比，低表达患者的无事件生存期和疾病特异性生存期的风险比（HR）分别为1.42和1.69。进一步结合TNM分期与HSP60表达进行生存分析发现，晚期/进展期且HSP60低表达的患者预后尤其不良。这一规律同样体现在编码HSP60的基因HSPD1上：低HSPD1表达与较低的总生存率和无复发生存率相关，HR值分别为1.80和1.87。当同时考量TNM分期与HSPD1表达时，低HSPD1表达且处于进展期的结直肠癌患者较高表达者预后更差。因此，HSPD1/HSP60可作为晚期及进展期结直肠癌精细化生存预测的有效生物标志物，为个体化治疗策略的制定提供依据。
Clinicopathologic Significance of Heat Shock Protein 60 as a Survival Predictor in Colorectal Cancer
肿瘤(癌症)患者之家